参考文献/References:
[1] Bautista LE, Lopez-Jaramillo P, Vera LM,et al.Is C-reactive protein an independent risk factor for essential hypertension?[J]. J Hypertens,2001,19:857-861.
[2] Schillaci G,Pirro M,Gemelli F,et al.Increased C-reactive protein concentrations in never-treated hypertension:the role of systolic and pulse pressures[J].J Hypertens,2003,21(10):1841-1846.
[3] Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension[J]. JAMA,2003,290(22):2945-2951.
[4] Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers and the risk of incident hypertension[J]. Hypertension,2007,49(3):432-438.
[5] 李艳秀,张怡,高平进.高敏C反应蛋白在高血压多种危险因素中敏感性与特异性最高[J].中华高血压杂志,2009,17:507-510.
[6] Chuang SY, Hsu PF, Chang HY,et al. C-reactive protein predicts systolic blood pressure and pulse pressure but not diastolic blood pressure: the Cardiovascular Disease Risk Factors Two-Township Study[J]. Am J Hypertens,2013,26(5):657-664.
[7] Davey Smith G,Lawlor DA,Harbord R,et al.Association of C-reactive protein with blood pressure and hypertension:life course confounding and mendelian randomization tests of causality[J].Arterioscler Thromb Vasc Biol,2005,25:1051-1056.
[8] Kong H, Qian YS, Zhu DL,et al. C-reactive protein(CRP)gene polymorphisms, CRP levels and risk of incident essential hypertension:findings from an observational cohort of Han Chinese[J]. Hypertens Res,2012,35:1019-1023.
[9] Sung SH, Chuang SY, Chen H, et al. Adiponectin, but not leptin or high-sensitivity C-reactive protein, is associated with blood pressure independently of general and abdominal adiposity[J]. Hypertens Res,2008,31:633-640.
[10] Eswar K. Interaction of inflammation, hyperuricemia, and the prevalence of hypertension among adults free of metabolic syndrome: NHANES 2009-2010[J]. J Am Heart Assoc,2014,3:e000157.
[11] Sorensen MV,Leonard WR,Tarskaya LA,et al.High-sensitivity C-reactive protein,adiposity,and blood pressure in the Yakut of Siberia[J].Am J Hum Biol,2006,18:766-775.
[12] Fichtlscherer S,Rosenberger G,Walter DH,et al.Elevated C-reactive protein levels and impaired endothelia1 vasoreactivity in patients with coronary artery disease[J].Circulation,2000,102(9):1000-1006.
[13] Hayaishi Okano R,Yamasaki Y,Katakami N,et al.Elevated C-reactive protein associates with early-stage carotid atherosclemsis in young subjects with type 1 diabetes[J].Diabetes Care,2002,25(8):1432-1438.
[14] Maeso R,Rodrigo E,Munoz-Garcia R,et al.Factors involved in the effects of losartan on endothelial dysfunction induced by aging in SHR[J]. Kidney Int,1998,68(2):230-235.
[15] Zwaka TP, Hombach V,Torzewski J.C-reactive protein mediated low density lipoprotein uptake by macrophages implications for atherosclerosis[J].Circulation,2001,103(9):1194-1197.
[16] Yasun K,Maeda K,Nakamura M, et al. Oxidative stress in leukocytes is a possible link between blood pressure,blood glucose,and C-reactive protein[J].Hypertension,2002,39(3):777-780.
[17] Vongpatanasin W, Thomas GD, Shaul PW,et al.C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice[J].Circulation,2007,115(8):1020-1028.
[18] Virdis A,Schifrin EL.Vascular inflammation:a role in vascular disease in hypertension[J].Curr Opin Nephrol Hypertens,2003,12:181-187.
[19] Hashimoto H, Kitagawa K, Hougaku H, et al. Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects[J]. Stroke,2004,35(7):1625-1630.
[20] Amer MS, Elawam AE, Khater MS,et al. Association of high-sensitivity C-reactive protein with carotid artery intima-media thickness in hypertensive older adults[J]. J Am Soc Hypertens,2011,5(5):395-400.
[21] Gomez-Marcos MA, Recio-Rodriguez JI, Patino-Alonso MC, et al. Relationships between high-sensitive C-reactive protein and markers of arterial stiffness in hypertensive patients.Differences by sex[J]. BMC Cardiovas Disord,2012,12:37.
[22] Conen D, Zeller A, Pfisterer M,et al. Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension[J]. Am J Cardiol,2006,97(2):249-252.
[23] Iwashima Y, Horio T, Kamide K,et al. C-reactive protein, left ventricular mass index, and risk of cardiovascular disease in essential hypertension[J]. Hypertens Res,2007,30(12):1177-1185.
[24] Ratto E,Leoncini G,Pontremoli R, et al. C-reactive protein and target organ damage in untreated patients with primary hypertension[J]. J Am Soc Hypertens,2007,1(6):407-413.
[25] Assadi F. C-reactive protein and incident left ventricular hypertrophy in essential hypertension[J]. Pediatr Cardiol,2007,28(4):280-285.
[26] Tsioufis C, Stougiannos P, Kakkavas A, et al.Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid A in patients with essential hypertension[J].Am J Cardiol,2005,96(2):252-256.
[27] Zhang R,Zhang YY,Huang XR,et al.C-reactive protein promotes cardiac fibrosis and inflammation in angiotensinⅡ-induced hypertensive cardiac disease[J]. Hypertension,2010,55:953-960.
[28] Tsioufis C, Dimitriadis K, Chatzis D, et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension[J]. Am J Cardiol,2005,96:946-951.
[29] Perticone F, Maio R, Tripepi G,et al. Endothelial dysfunction and mild renal insufficiency in essential hypertension[J]. Circulation,2004,110:821-825.
[30] Zoccali C, Maio R, TripepiG,et al. Inflammation as a mediator of the link between mild to moderate renal insufficiency and endothelial dysfunction in essential hypertension[J]. J Am Soc Nephrol,2006,17: S64-S68.
[31] Xu TY, Zhang Y, Li Y,et al.The association of serum in flammatory biomarkers with chronic kidney disease in hypertensive patients[J].Ren Fail,2014,36(5):666-672.
[32] Ridker PM, Danielson E, Fonseca FA,et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial[J].Lancet,2009,373(9670):1175-1182.
[33] Palmas W, Ma S, Psaty B,et al. Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis[J]. Am J Hypertens,2007,20(3):233-241.
[34] Fulop T, Rule AD, Schmidt DW, et al. C-reactive protein among community-dwelling hypertensive on single-agent antihypertensive treatment[J]. J Am Soc Hypertens,2009,3(4):260-266.
相似文献/References:
[1]张宝丽,许建忠,综述,等.副肾动脉与高血压的研究进展[J].心血管病学进展,2016,(3):224.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.002]
ZHANG Baoli,XU Jianzhong,TANG Xiaofeng,et al.Accessory Renal Artery and Hypertension[J].Advances in Cardiovascular Diseases,2016,(5):224.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.002]
[2]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(5):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[3]段兴连,综述,常静,等.阻塞性睡眠呼吸暂停低通气综合征及其干预治疗对心血管疾病的临床意义[J].心血管病学进展,2016,(3):289.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.019]
DUAN Xinglian,CHANG Jing.Clinical Significance of OSAHS and Its Intervention Therapy on
Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(5):289.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.019]
[4]梅宝菲,孔一慧,李为民.睡眠障碍与心血管疾病研究新进展[J].心血管病学进展,2015,(5):603.[doi:10.3969/j.issn.1004-3934.2015.05.020]
MEI Baofei,KONG Yihui,LI Weimin.Relationship Between Somnipathy and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2015,(5):603.[doi:10.3969/j.issn.1004-3934.2015.05.020]
[5]成哲,罗素新,夏勇.LCZ696在心血管疾病中的研究进展[J].心血管病学进展,2015,(5):606.[doi:10.3969/j.issn.1004-3934.2015.05.021]
CHENG Zhe,LUO Suxin,XIA Yong.Research Progress of LCZ696 in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2015,(5):606.[doi:10.3969/j.issn.1004-3934.2015.05.021]
[6]冯颖青.β受体阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):665.[doi:10.3969/j.issn.1004-3934.2015.06.003]
FENG Yingqing.Role of Beta-blocker in Antihypertensive Treatment[J].Advances in Cardiovascular Diseases,2015,(5):665.[doi:10.3969/j.issn.1004-3934.2015.06.003]
[7]袁静,郭艺芳.利尿剂在降压治疗中的应用[J].心血管病学进展,2015,(6):668.[doi:10.3969/j.issn.1004-3934.2015.06.004]
YUAN Jing,GUO Yifang.Application of Diuretics in Antihypertensive Treatment[J].Advances in Cardiovascular Diseases,2015,(5):668.[doi:10.3969/j.issn.1004-3934.2015.06.004]
[8]张新军.肾素-血管紧张素系统拮抗剂在高血压治疗中的应用[J].心血管病学进展,2015,(6):673.[doi:10.3969/j.issn.1004-3934.2015.06.005]
ZHANG Xinjun.Effects of Renin-angiotensin System Antagonists on Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2015,(5):673.[doi:10.3969/j.issn.1004-3934.2015.06.005]
[9]刘茜,黄晶.顽固性高血压的诊断和治疗[J].心血管病学进展,2015,(6):713.[doi:10.3969/j.issn.1004-3934.2015.06.014]
LIU Xi,HUANG Jing.Diagnosis and Treatment of Resistant Hypertension[J].Advances in Cardiovascular Diseases,2015,(5):713.[doi:10.3969/j.issn.1004-3934.2015.06.014]
[10]高珩 邓超 李媛媛 钟亮 王雪.急性Stanford A型主动脉夹层患者术前炎症、凝血相关标志物及肌酐清除率与术后死亡的关系研究[J].心血管病学进展,2022,(12):1134.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.018]
GAO Heng,DENG Chao,LI Yuanyuan,et al.Relationship of Preoperative Inflammation and Clotting Related Biomarkers ,Creatinine Clearance Rate with Postoperative Death in Patients with Acute Stanford Type A Aortic Dissection[J].Advances in Cardiovascular Diseases,2022,(5):1134.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.018]